BRIM Biotechnology

May 12, 2022

Beyond **R**esearch and **I**nnovative **M**edicines

BRIM 全福生物科技 biotechnology

Founders

Haishan Jang, PhD

Chief Executive Officer &
BRIM Taiwan Chairman
30+ years experience

- Previously a member of Senior Management at Centocor
- Former Manager at DuPont and Sanofi
- Former President at TWI Biotechnology (Taiwan)
- Drug development of Uroxatral, Tirazon, Remicade, Simponi, and Stelara

centocor DUPONT SANOFI

Frank Lee, PhD

Chief Strategy Officer &
BRIM Cayman Chairman
41+ years experience

- Previously Vice President of DMPK at Takeda
- Former member of Senior Management at Millennium Pharmaceuticals and DuPont Pharma
- Drug development of Naprosyn, Anaprox, Ticlid, Toradol, Avodart, Flonase, Imitrex, Zofran, Sustiva, Velcade, Entyvio® and Ixazomib

DUPONT MILLENNIUM Takeda

Our approach

Maximize ROI through early exit at clinical proof of concept (PoC)

Reduced IND enabling time (1.5-3 years from lead ID to IND submission)

Good budget control of both R&D and fixed cost



Global DES population:

915m

severe DES:
~90m

DES Market



2021 GLOBAL MARKET SIZE:

5.21 Billion USD[1]

2027 GLOBAL MARKET SIZE PROJECTION:

~7 Billion USD[1]

CAGR (2019-2027)

5.12%[1]

References:
1. https://www.mordorintelligence.com/industry-reports/dry-eye-disease-market

Beyond the Current Standard of Care

BRM421 Unique MoA

Stimulate proliferation and differentiation of corneal limbal stem cells to speed up cornea repair process

Promote proliferation and differentiation of goblet cells to improve tear quality





DES competitors on market

COMPANY/DRUGS	DRUG TYPE	MOA / API	STATUS	ONSET (WEEKS)	FREQUENCY	SIDE EFFECT	PATENT	COMMENTARY
BRIM/ BRM421	Peptide	stem cell regeneration/ PEDF-derived peptide	US Phase 2	2	3x daily	Instillation site reaction (37%)	2041	Visual Improvement
NOVARTIS/ XIIDRA	Small molecule	Anti-inflammation / LFA antagonist	US approved EU withdrawn	12	2x daily	Irritation (18%), Dysgeusia (13%)	2033	$7,600/yr
ALLERGAN (ABBVIE)/ RESTASIS	Peptide	Anti-inflammation / ciclosporin	US approved CN trial	24	2x daily	Burning, stinging (17%)	2024	$7,600/yr
KALA/ EYSUVIS	Small molecule	Anti-inflammation / nano particle steroid	US approved	2	4x daily	Conjunctivitis	2033	Steroid may have risks for IOP
Oyster Point/ TYRVAYA	Small molecule	tear production/ nicotinic acetylcholine receptor agonist	US approved	4	2x daily	sneezing (82%), cough (16%), throat irritation (13%)	2035	nasal spray; poor patient adherence
ESSEX / bFGF	Protein	Cornea repair / FGF	CN approved	2	6x daily	Cannot use over two weeks	N/A	Increases cancer risk
UNI-BIO / rhEGF	Protein	Cornea repair / EGF	CN approved	2	4x daily	Cannot use over two weeks	N/A	Increases cancer risk
SANTEN/ DIQUAS	Small molecule	Tear quality / P2Y2 receptor agonist	JPN approved CN approved US P3	4	6x daily	Hypersensitivity, Itching, irritation, conjunctivitis	2023	NA
OTSUKA/ MUCOSTA	Small molecule	Tear quality / prostaglandin agonist	JPN approved US failed	4	4x daily	Dysgeusia (9.7%)	2026	NA

BRIM has Licensed BRM421 CN Rights to China Grand Pharm

China Grand Pharm (CGP), HK: 0512

the 5th largest healthcare group in China

CGE 远大健康 CGE HEALTHCARE

Over USD 85M

total deal size

China
Hong Kong
Macau

regional rights

BRM421 efficacy in mouse DES model

Mice housed at CEC for 14 days without topical treatment

Drug dosing 3x a day for seven days in a normal environment

Topical BRM421 displays therapeutic effect in experimental murine dry eye.
(2-way ANOVA; *P < 0.002 *vs.* day 0/ CEC seven days)







Dex: Dexamethasone
CMC: Carboxymethyl cellulose

PDSP 29mer can effectively regenerate healthy limbus after extensive limbal layer removal (Rabbit Model)





First-in-Human Study Showed a Positive Trend:

Effective in Treating DES

Sign



Ad Hoc Analysis:
Mean change from Baseline in sign from fluorescein total corneal staining scores in moderate to severe DES patients

Symptom



Ad Hoc Analysis:
Mean change from Baseline in Dryness from Ora Calibra® Ocular Discomfort & 4-Symptom in moderate to severe DES patients

* $p < 0.05$

BRM421 is ready for Phase III study

	Phase II/III	Phase III	
Enrollment Criteria	Moderate-to-severe	Moderate-to-severe	* same design
Duration	14 days	14 days	* same design
Endpoint: Sign	Fluorescein total corneal staining at Visit 4 (Day 15)	Fluorescein total corneal staining at Visit 4 (Day 15)	* same design
Endpoint: Symptom	Ocular Discomfort & 4-Symptom	Visual Analogue Scale (VAS)	* based on SIH data; FDA agreed (Type C)
Formulation Stabilizer	High concentration	Low concentration	* no additional tox needed; FDA agreed (Type C)
Enrollment Number	220	~700	* calculated from SIH patient variability

Development milestones



Thank you

Contact Person:
Yi-Chun Maria Chen
VP of Business Development
yichun.chen@brimbiotech.com

Beyond **R**esearch and **I**nnovative **M**edicines

BRIM 全福生物科技 biotechnology